Loading...

ENG KOR

KB STAR ETF 로고

홈으로 이동

KOR ENG

ETF Finder

Home Product Lineup ETF Finder Product Details
Domestic
Equity active

RISE Bio TOP10 Active (0000Z0)

Update : 2026.06.19

NAV

11,017KRW

-330.71하락 (-2.91%)

Market Price per share (KRW)

10,970KRW

-360하락 (-3.18%)

※ t-1 last price

trading volume

459,865shares

AUM

KRW 65.5billion

Share it

RISE Bio TOP10 Active (0000Z0)

Overview Performance Holdings

KEY POINT

An Active ETF Investing in 10 Key Domestic Pharmaceutical and Bio Companies Expanding Globally

-

KEY POINT

An Active ETF Designed to Quickly Respond to Technological Advancements, Regulatory Changes, Drug Approvals, and Individual Company Events.

-

Basic information

Download trading information

Update : 2026.06.19
ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code) Benchmark Index Inception date Creation Unit AUM (KRW)
KB RISE Bio TOP10 Active ETF
(0000Z0) 		KRX Bio TOP 10 Index 2024.12.24 50,000 65,550,640,123
Trustee Market Price per share (KRW) NAV Trading Volume (shares)
한국씨티은행 10,970
※ t-1 last price 		11,016 459,865
authorized participant, Liquidity provider table
Total Expense Ratio Distribution Frequency
Year 0.5% (Designated participating company : 0.001%, Collective investment : 0.459%, trust : 0.02%, General affairs : 0.02%) End date of the accounting period (If the end of the accounting period is not a business day, the business day immediately preceding it)
Authorized Participants Liquidity Providers
Kiwoom Securities, NH Investment & Securities, KB Securities Kiwoom Securities, NH Investment & Securities, KB Securities
ETF name(Code), Benchmark Index, Inception date, creation unit, AUM(0.1 billion) (KRW), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name(Code) Benchmark Index
KB RISE Bio TOP10 Active ETF

(0000Z0) 		KRX Bio TOP 10 Index
Inception date Creation Unit
2024.12.24 50,000
AUM(0.1 billion) (KRW) Trustee
65,550,640,123 한국씨티은행
Market Price per share (KRW) iNAV per share (KRW)
10,970
※ t-1 last price 		11,016
Trading Volume (shares)
459,865
authorized participant, Liquidity provider table
Total Expense Ratio
Year 0.5% (Designated participating company : 0.001%, Collective investment : 0.459%, trust : 0.02%, General affairs : 0.02%)
Distribution Frequency
End date of the accounting period (If the end of the accounting period is not a business day, the business day immediately preceding it)
Authorized Participants
Kiwoom Securities, NH Investment & Securities, KB Securities
Liquidity Providers
Kiwoom Securities, NH Investment & Securities, KB Securities

Index Introduction

The 'KRX Bio TOP 10 Index', calculated and announced by the Korea Exchange (KRX), consisting of 10 representative companies within the Bio industry sector listed on the KOSPI and KOSDAQ markets.

View detailed index information

TOP 10 Holdings

Update : 2026-06-19
Rank , Name, proportion table
Rank Name Weight (%)
1 Alteogen 11.33
2 OliX 10.99
3 LCB 9.36
4 ABL Bio 7.30
5 D&D Pharmatech 6.76
6 Celltrion 4.65
7 ST Pharm 4.12
8 HANALL BIOPHARMA 3.96
9 Kolon TissueGene 3.70
10 Hugel 3.54

proportion by sectors

*The proportion of investment stocks

Update : 2026.06.19
Rank , Name, proportion table
Rank Name Weight (%)
1 Healthcare 98.50
2 Information Technology 1.49

Dividend payment data

· Payable date of dividend payment 3 years.
Rule of Dividend payment, Payable date of dividend payment, dividend per share (KRW) table
Rule of Dividend payment Payable date of dividend payment dividend per share (KRW)
2025-12-30 2026-01-05 2

Performance

performance

excel download

Update : 2026-06-19

 (as of Oct : %)

The result of above Net Asset Value performance is the rate of return assuming distribution reinvestment.

classification, 1Month, 3Month, 6Month, 1year, 3year, YTD (Year to date), Since inception, NAV, Benchmark Index, Outperformance table
classification 1Month 3Month 6Month 1year 3year YTD
(Year to date)		 Since
inception
NAV -12.63 -39.01 -27.39 -1.66 - -28.52 14.25
Benchmark Index -3.19 -13.86 -19.09 -3.76 - -20.01 1.22
Outperformance -9.45 -25.15 -8.31 2.09 - -8.51 13.03

daily Performance

excel download

-
search
date, market price (KRW), NAV (KRW)
date Market price (KRW) NAV (KRW) Standard Tax Base Price (KRW)
closing price Daily Return(%) closing price Daily Return(%)
2026.06.19 10,970 -3.177하락 11,016.91 -2.914하락 9,569.77
2026.06.18 11,330 -4.789하락 11,347.62 -4.760하락 9,569.92
2026.06.17 11,900 6.344상승 11,914.87 6.532상승 9,570.07
2026.06.16 11,190 2.519상승 11,184.27 2.897상승 9,570.23
2026.06.15 10,915 1.724상승 10,869.34 1.426상승 9,570.38
2026.06.12 10,730 -2.410하락 10,716.76 -2.811하락 9,570.82
2026.06.11 10,995 3.385상승 11,026.81 3.639상승 9,570.97
2026.06.10 10,635 -2.026하락 10,639.57 -1.922하락 9,571.12
2026.06.09 10,855 6.945상승 10,848.1 7.104상승 9,571.3
2026.06.08 10,150 -13.432하락 10,128.53 -13.773하락 9,571.46
2026.06.05 11,725 -4.674하락 11,746.73 -4.627하락 9,571.93
2026.06.04 12,300 0.162상승 12,316.72 0.385상승 9,572.09
2026.06.02 12,280 -3.230하락 12,269.56 -3.286하락 9,572.44
2026.06.01 12,690 -3.203하락 12,686.5 -3.789하락 9,572.61
2026.05.29 13,110 -3.354하락 13,186.52 -3.568하락 9,573.14
2026.05.28 13,565 -2.968하락 13,674.48 -2.283하락 9,573.32
2026.05.27 13,980 2.869상승 13,994.02 3.320상승 9,573.51
2026.05.26 13,590 1.304상승 13,544.34 0.799상승 9,573.71
2026.05.22 13,415 6.807상승 13,437.48 7.492상승 9,574.45
2026.05.21 12,560 2.572상승 12,500.81 2.068상승 9,574.64

Holdings

search
Download holdings data
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number) Name Ticker Number of shares Weight(%) Market price (KRW)
1 Alteogen KR7196170005 174 11.33 64,293,000
2 OliX KR7226950004 462 10.99 62,370,000
3 LCB KR7141080002 395 9.36 53,127,500
4 ABL Bio KR7298380007 409 7.3 41,431,700
5 D&D Pharmatech KR7347850000 354 6.76 38,338,200
6 Celltrion KR7068270008 152 4.65 26,387,200
7 ST Pharm KR7237690003 184 4.12 23,368,000
8 HANALL BIOPHARMA KR7009420001 409 3.96 22,454,100
9 Kolon TissueGene KR8840120008 197 3.7 21,000,200
10 Hugel KR7145020004 80 3.54 20,080,000
11 HanmiPharm KR7128940004 46 3.45 19,573,000
12 AprilBio KR7397030008 464 3.38 19,163,200
13 OCT Inc. KR7039200001 475 3.32 18,833,750
14 Rznomics KR7476830005 184 2.93 16,615,200
15 HANS BIOMED KR7042520007 612 2.62 14,871,600
16 LivsMed KR7491000006 349 2.6 14,727,800
17 AbClon KR7174900001 446 2.48 14,093,600
18 VRNI KR7310210000 62 2.21 12,555,000
19 RecensMedical KR7394420004 530 2.06 11,660,000
20 PEPTRON KR7087010005 53 2.02 11,474,500
21 the curacle KR7365270008 617 1.57 8,897,140
22 GI Innovation KR7358570000 685 1.52 8,617,300
23 HLB innoVation KR7024850000 622 1.51 8,583,600
24 G2GBIO KR7456160001 136 1.07 6,092,800
25 S.Biomedics KR7304360001 214 0.92 5,221,600
26 원화예금 KRD010010001 3,550,875 0.63 3,550,875
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.